TO THE NATIONAL SECRETARIATS OF FILCTEM-CGIL FEMCA-CISL UILCEM-UIL
SUBJECT: The slaughter of the ISF continues.
It is news in the last few hours that Pfizer will open a mobility procedure that will affect 192 workers, most of whom are ISF (158) from the Primary Care line. More ISFs who lose their jobs adding to the many who have already lost or are losing it.
Recently mobility procedures (or other methods of expelling workers) have involved important pharmaceutical groups such as BMS, Sanofi-Aventis, Sigma Tau, MSD, Rottapharma, Novartis and others which add to the many "company crises" actually or artificially implemented in the last few years.
By now, any estimate of the number of workers in the sector thrown out of the labor market, in the "most deafening of silences", is no longer reliable. One thing is certain and evident: most of them (almost all!) are among the ISF.
Analyzes that aim to find reasons almost always focus on four topics:
1. Patents are almost all expiring and therefore "generic" drugs suffer from aggressive competition from equivalents.
2. In the short and medium term, the launch of new drugs, which in any case would be highly specialized and therefore niche, is not foreseen.
